According to GlobalData, the remote patient monitoring sector will generate $760m in 2030. Credit: Pixel-Shot via Shutterstock.

Pavmed’s digital health subsidiary Veris Health and the Ohio State University Comprehensive Cancer Center – Arthur G James Cancer Hospital and Richard J Solove Research Institute (OSUCCC – James) have entered a memorandum of understanding to roll out a pilot programme of the Veris Cancer Care platform (CCP). 

The Veris CCP is a digital tool for comprehensive cancer care, offering remote data collection, symptom reporting, telehealth, and electronic health record (EHR) integration. It aims to detect complications early to reduce unplanned hospitalisations. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cancer patients who are enrolled in the Veris CCP pilot will receive a VerisBox that includes Bluetooth-enabled connected healthcare devices. Through a smartphone app and Cloud-based Veris CCP clinician portal, the healthcare devices transmit patients’ clinical data to the cancer care team. 

Veris announced the commercial rollout of the remote patient monitoring device back in December 2022. In PAVmed’s 2023 business update and financial results, the company highlighted that Veris will begin to shift its commercial strategy to target large academic and regional cancer centres. 

Remote patient monitoring is the process of using technology to monitor patients in non-clinical environments, such as in the home. It has grown in popularity over the last few years, as it can increase the quality of life for patients with certain conditions by being monitored at home. 

According to a report on GlobalData’s Medical Intelligence Center, the remote patient monitoring sector is expected to be worth $760m by 2030. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

David Cohn, chief medical officer at OSUCCC – James, said: “Remote monitoring allows for the integration of expert, sub-specialised oncology care in a patient’s own home, surrounded by their support system. This component of the cancer care continuum is yet another way we are engaging in the future of cancer care and is in line with our pursuit of a cancer-free world.” 

In February 2023, Macmillan Cancer Support invested £100,000 ($124,888) in medtech start-up 52 North Health. The company is developing a remote device that can detect neutropenic sepsis in cancer patients undergoing chemotherapy. The NeutroCheck device pairs with a digital app that allows patients to monitor for neutropenic sepsis at home following a lateral flow test from a blood finger prick.